These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 30957864)

  • 21. Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.
    Riaz H; Khan MS; Schenone AL; Waheed AA; Khan AR; Krasuski RA
    Am Heart J; 2018 May; 199():44-50. PubMed ID: 29754665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Closure of the patent foramen ovale (PFO) in cryptogenic stroke].
    Diener HC; Knebel F
    Herz; 2019 Jun; 44(4):304-309. PubMed ID: 30941472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
    Moon J; Kim M; Oh PC; Shin DH; Park HM; Jo YY; Lee JS; Kang WC
    J Stroke Cerebrovasc Dis; 2019 Feb; 28(2):347-353. PubMed ID: 30396838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patent foramen ovale from the point of view of interventional cardiology.
    Poloczek M; Kala P; Ondrúš T
    Vnitr Lek; 2021; 67(1):22-28. PubMed ID: 33752387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment.
    Melkumova E; Thaler DE
    Interv Cardiol Clin; 2017 Oct; 6(4):487-493. PubMed ID: 28886840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventional closure vs. medical therapy of patent foramen ovale for secondary prevention of stroke: updated meta-analysis.
    Vukadinović D; Schirmer SH; Vukadinović AN; Ukena C; Scheller B; Mahfoud F; Böhm M
    Clin Res Cardiol; 2019 Feb; 108(2):157-166. PubMed ID: 30051178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Percutaneous closure of patent foramen ovale for cryptogenic stroke: a meta-analysis of randomized controlled trials.
    Kwong JS; Lam YY; Yu CM
    Int J Cardiol; 2013 Oct; 168(4):4132-8. PubMed ID: 23890879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of Transcatheter Closure of Patent Foramen Ovale in Clinical Practice.
    Alkhouli M; Van Houten HK; Yao X; Holmes DR
    J Am Heart Assoc; 2023 Aug; 12(15):e030321. PubMed ID: 37489748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update.
    Abdelghani M; El-Shedoudy SAO; Nassif M; Bouma BJ; de Winter RJ
    Cardiology; 2019; 143(1):62-72. PubMed ID: 31307049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patent foramen ovale-When to close and how?
    Maloku A; Hamadanchi A; Franz M; Dannberg G; Günther A; Klingner C; Schulze PC; Möbius-Winkler S
    Herz; 2021 Oct; 46(5):445-451. PubMed ID: 34463786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis.
    Shah R; Nayyar M; Jovin IS; Rashid A; Bondy BR; Fan TM; Flaherty MP; Rao SV
    Ann Intern Med; 2018 Mar; 168(5):335-342. PubMed ID: 29310136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
    Mas JL; Derex L; Guérin P; Guillon B; Habib G; Juliard JM; Marijon E; Massardier E; Meneveau N; Vuillier F
    Arch Cardiovasc Dis; 2019; 112(8-9):532-542. PubMed ID: 31378692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Stroke: Meta-Analysis of Randomised Trials.
    Wang TKM; Wang MTM; Ruygrok P
    Heart Lung Circ; 2019 Apr; 28(4):623-631. PubMed ID: 29602754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patent foramen ovale (PFO) closure to prevent recurrent stroke in a patient with a nickel allergy.
    Rizvi AA; Margey R; Kiernan F
    Conn Med; 2014 Apr; 78(4):215-9. PubMed ID: 24830118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patent foramen ovale closure to prevent secondary neurologic events.
    Jasper R; Blankenship JC
    Eur J Intern Med; 2017 Oct; 44():1-11. PubMed ID: 28684051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ten years of experience with closure of persistent foramen ovale: patient characteristics and outcomes.
    Lehmann R; Fichtlscherer S; Baldauf H; Schächinger V; Auch-Schwelck W; Zeiher AM; Teupe C
    J Cardiol; 2014 Aug; 64(2):113-6. PubMed ID: 24480741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Updates on Patent Foramen Ovale (PFO) Closure.
    Voudris KV; Poulin MF; Kavinsky CJ
    Curr Cardiol Rep; 2024 Jul; 26(7):735-746. PubMed ID: 38913234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patent foramen ovale closure or medical therapy for cryptogenic ischemic stroke: an updated meta-analysis of randomized controlled trials.
    Schulze V; Lin Y; Karathanos A; Brockmeyer M; Zeus T; Polzin A; Perings S; Kelm M; Wolff G
    Clin Res Cardiol; 2018 Sep; 107(9):745-755. PubMed ID: 29500568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Outcome After Percutaneous Closure of Patent Foramen Ovale for Cryptogenic Ischemic Events.
    Seeger J; Uber A; Wöhrle J
    J Invasive Cardiol; 2019 Aug; 31(8):E242-E248. PubMed ID: 31368895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.